MedTrace Logo

RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma

NCT04176380 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-05-15

No results posted yet for this study

Summary

RAPA-201-RRMM is an open-label, single-arm, non-randomized multicenter phase II study of RAPA-201 autologous T cells in adults with relapsed, refractory multiple myeloma who have received at least three (3) prior lines.

Conditions

  • Relapsed, Refractory Multiple Myeloma

Interventions

BIOLOGICAL

RAPA-201 Autologous T cells

Autologous rapamycin resistant Th1/Tc1 cells

Sponsors & Collaborators

  • Medical College of Wisconsin

    collaborator OTHER

  • Rapa Therapeutics LLC

    lead INDUSTRY

Principal Investigators

  • Daniel Fowler, M.D. · Rapa Therapeutics LLC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-02
Primary Completion
2023-01-30
Completion
2023-06-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04176380 on ClinicalTrials.gov